CEO and President of Oncocyte Corp (30-Year Financial, Insider Trades) Ronald Asbury Andrews (insider trades) bought 45,216 shares of OCX on 03/31/2020 at an average price of $945.63 a share. The total cost of this purchase was $42.8 million.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. OncoCyte Corp has a market cap of $131.200 million; its shares were traded at around $2.10 . OncoCyte Corp had annual average EBITDA growth of 6.50% over the past five years. GuruFocus has detected 1 severe warning sign with OncoCyte Corp. .
CEO Recent Trades:
- CEO and President Ronald Asbury Andrews bought 45,216 shares of OCX stock on 03/31/2020 at the average price of $945.63.
For the complete insider trading history of OCX, click here
.